Thomas P. Loughran

16.7k total citations · 2 hit papers
251 papers, 10.3k citations indexed

About

Thomas P. Loughran is a scholar working on Immunology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Thomas P. Loughran has authored 251 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Immunology, 106 papers in Genetics and 80 papers in Pathology and Forensic Medicine. Recurrent topics in Thomas P. Loughran's work include Chronic Lymphocytic Leukemia Research (99 papers), Lymphoma Diagnosis and Treatment (78 papers) and Immune Cell Function and Interaction (61 papers). Thomas P. Loughran is often cited by papers focused on Chronic Lymphocytic Leukemia Research (99 papers), Lymphoma Diagnosis and Treatment (78 papers) and Immune Cell Function and Interaction (61 papers). Thomas P. Loughran collaborates with scholars based in United States, France and India. Thomas P. Loughran's co-authors include Thierry Lamy, Gordon Starkebaum, Pearlie K. Epling‐Burnette, Lubomir Sokol, David J. Feith, Ravi Kothapalli, Réka Albert, Jin Hong Liu, Mark Kester and Xin Liu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Thomas P. Loughran

243 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

1991 626 citations Thomas P. Loughran et al. profile →
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

2001 505 citations Pearlie K. Epling‐Burnette, Jin Hong Liu et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas P. Loughran United States	55	4.5k	3.4k	3.2k	3.0k	2.3k	251	10.3k
Christer Sundström Sweden	54	3.8k 0.8×	3.1k 0.9×	5.0k 1.6×	3.0k 1.0×	3.8k 1.7×	270	12.3k
Alberto Órfão Spain	66	5.8k 1.3×	3.4k 1.0×	2.7k 0.8×	4.5k 1.5×	3.1k 1.4×	463	16.1k
Jeffrey Cossman United States	46	2.9k 0.6×	2.4k 0.7×	3.4k 1.1×	3.3k 1.1×	2.9k 1.3×	112	9.3k
Andrew W. Roberts Australia	67	4.7k 1.0×	4.9k 1.4×	3.2k 1.0×	7.6k 2.5×	5.0k 2.2×	275	17.4k
Ulf Klein United States	55	7.5k 1.6×	2.5k 0.7×	3.3k 1.0×	5.7k 1.9×	3.1k 1.4×	105	15.0k
Martin J.S. Dyer United Kingdom	71	4.9k 1.1×	6.1k 1.8×	6.5k 2.0×	6.3k 2.1×	4.6k 2.0×	300	16.5k
Svetomir N. Markovic United States	60	4.0k 0.9×	1.1k 0.3×	1.7k 0.5×	3.4k 1.1×	6.9k 3.0×	349	12.2k
Wyndham H. Wilson United States	66	4.8k 1.1×	4.8k 1.4×	8.2k 2.5×	4.0k 1.3×	9.0k 3.9×	329	17.6k
Giorgio Cattoretti Italy	54	4.9k 1.1×	2.2k 0.6×	3.6k 1.1×	6.6k 2.2×	4.2k 1.8×	183	16.3k
Catherine J. Wu United States	57	6.4k 1.4×	1.9k 0.6×	1.4k 0.4×	5.4k 1.8×	6.3k 2.8×	270	14.2k

Countries citing papers authored by Thomas P. Loughran

Since Specialization

Citations

This map shows the geographic impact of Thomas P. Loughran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas P. Loughran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas P. Loughran more than expected).

Fields of papers citing papers by Thomas P. Loughran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas P. Loughran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas P. Loughran. The network helps show where Thomas P. Loughran may publish in the future.

Co-authorship network of co-authors of Thomas P. Loughran

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas P. Loughran. A scholar is included among the top collaborators of Thomas P. Loughran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas P. Loughran. Thomas P. Loughran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marchi, Enrica, Tapan M. Kadia, Christina Poh, et al.. (2025). Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia. Blood. 146(Supplement 1). 777–777.

Tsuboi, Kazuhito, Josefina Casas, Su‐Fern Tan, et al.. (2024). A fluorogenic substrate for the detection of lipid amidases in intact cells. Journal of Lipid Research. 65(3). 100520–100520. 1 indexed citations

Marchand, Tony, et al.. (2024). A modern view of LGL leukemia. Blood. 144(18). 1910–1923. 5 indexed citations

O’Connor, Owen A., Anuradha Illendula, Kallesh D. Jayappa, et al.. (2023). Synthesis and Preclinical Development of a Promising Novel Romidepsin Nanoparticle for the Treatment of Peripheral T‐Cell Lymphoma (PTCL). Hematological Oncology. 41(S2). 548–548. 1 indexed citations

Brammer, Jonathan E., Karen K. Ballen, Lubomir Sokol, et al.. (2023). Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. Blood. 142(15). 1271–1280. 12 indexed citations

Loughran, Thomas P., et al.. (2022). Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center. Cancer Prevention Research. 15(11). 715–720.

Tan, Su‐Fern, Pavan Kumar Dhanyamraju, Zheng Zeng, et al.. (2020). The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. Frontiers in Oncology. 10. 393–393. 16 indexed citations

Pearson, Jennifer M., Su‐Fern Tan, Arati Sharma, et al.. (2019). Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. Molecular Cancer Research. 18(3). 352–363. 23 indexed citations

Olson, Kristine C., et al.. (2018). Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS ONE. 13(2). e0193429–e0193429. 15 indexed citations

10.

Steinway, Steven N., Jorge Gómez Tejeda Zañudo, Wei Ding, et al.. (2014). Network Modeling of TGFβ Signaling in Hepatocellular Carcinoma Epithelial-to-Mesenchymal Transition Reveals Joint Sonic Hedgehog and Wnt Pathway Activation. Cancer Research. 74(21). 5963–5977. 188 indexed citations

11.

Steinway, Steven N., Francis LeBlanc, & Thomas P. Loughran. (2014). The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Reviews. 28(3). 87–94. 50 indexed citations

12.

Perzova, Raisa, Patricia Benz, Lynn Abbott, et al.. (2014). Increased Seroreactivity to Human T Cell Lymphoma/Leukemia Virus-Related Endogenous Sequence-1 Gag Peptides in Patients with Human T Cell Lymphoma/Leukemia Virus Myelopathy. AIDS Research and Human Retroviruses. 31(2). 242–249. 5 indexed citations

13.

Talamo, Giampaolo, et al.. (2014). Report of 6 Cases of Large Granular Lymphocytic Leukemia and Plasma Cell Dyscrasia. Clinical Lymphoma Myeloma & Leukemia. 14(5). e169–e172. 8 indexed citations

14.

Yu, Jianhua, Takeki Mitsui, Wei Min, et al.. (2011). NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. Journal of Clinical Investigation. 121(4). 1456–1470. 58 indexed citations

15.

Sekeres, Mikkael A., Alan F. List, David Cuthbertson, et al.. (2010). Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology. 28(13). 2253–2258. 86 indexed citations

16.

Thomas, Anish, Raisa Perzova, Lynn Abbott, et al.. (2010). LGL Leukemia and HTLV. AIDS Research and Human Retroviruses. 26(1). 33–40. 22 indexed citations

17.

Hodge, Deborah L., Jun Yang, Matthew D. Buschman, et al.. (2009). Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias. Cancer Research. 69(9). 3986–3994. 50 indexed citations

18.

Thomas, Johnson, Joseph K. Haseman, Jay I. Goodman, et al.. (2007). A Review of Large Granular Lymphocytic Leukemia in Fischer 344 Rats as an Initial Step Toward Evaluating the Implication of the Endpoint to Human Cancer Risk Assessment. Toxicological Sciences. 99(1). 3–19. 26 indexed citations

19.

Epling‐Burnette, Pearlie K., Jin Hong Liu, Robyn Catlett-Falcone, et al.. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. Journal of Clinical Investigation. 107(3). 351–362. 505 indexed citations breakdown →

20.

Aprile, J, et al.. (1990). Interleukin-2 receptor monoclonal antibodies have no effect on anti-CD3 monoclonal antibody-mediated cytotoxicity in CD3+ leukemic large granular lymphocytes. Cellular Immunology. 131(2). 404–408. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact